urinary%20incontinence%20in%20women
URINARY INCONTINENCE IN WOMEN
Urinary incontinence is the complaint of involuntary urine leakage.
Stress urinary incontinence is the involuntary urine leakage on effort or exertion or when coughing or sneezing.
Urge urinary incontinence is the one associated with or immediately preceded by urgency.
Mixed urinary incontinence is the involuntary urine leakage associated with both urgency and with exertion, effort, coughing or sneezing.

Definition

  • Urinary incontinence (UI) is defined as complaint of involuntary urine leakage

Risk Factors

  • Irreversible factors
    • Age, race, educational attainment, family history, childhood enuresis, multiparity, forceps delivery, hysterectomy, surgery for pelvic organ prolapse
  • Reversible factors
    • Body mass index (BMI) >30, smoking, high caffeine intake, participation in high-impact sports, diabetes, depression, central nervous system (CNS) disorders, recurrent urinary tract infection (UTI), constipation, drugs, pelvic organ prolapse, environmental barriers
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elaine Soliven, 12 Jan 2018
Use of metformin during the first trimester of pregnancy showed no significant maternal or foetal adverse outcomes in women with gestational diabetes mellitus (GDM), according to a study presented at IDF 2017.
Roshini Claire Anthony, 12 Jan 2018

The use of a cervical pessary may reduce the risk of preterm birth in women with singleton pregnancies and short cervical length, according to a single-centre study from Italy.

26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.